EUCTR2020-000743-31-DE进行中（未招募）1 期
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer - MARIPOSA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 1,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Participant must be =18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place).
- •2. Participant must have newly diagnosed, histologically or cytologically confirmed, locally advanced or metastatic NSCLC that is treatment naïve and not amenable to curative therapy including surgical resection or chemoradiation.
- •3. The tumor (meeting criteria described in Inclusion Criterion no. 2) harbors Exon 19del or Exon 21 L858R substitution, as detected by an FDA-approved or other validated test in a CLIA certified laboratory (sites in the US) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care. (Note: A copy of the test report documenting the EGFR mutation must be included in the participant records and must also be submitted to the sponsor.)
- •4. Mandatory submission of unstained tissue from tumor meeting criteria described in Inclusion Criterion no. 2 (in a quantity sufficient to allow for central analysis of EGFR mutation status) and blood (for ctDNA, digital droplet polymerase chain reaction
- •[ddPCR], and pharmacogenomic analysis).
- •5. Any toxicities from prior anticancer therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) Grade 1 or baseline level.
- •6. Participant must have at least 1 measurable lesion, according to RECIST v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy.
- •7. Participant must have adequate organ and bone marrow function as follows, without history of red blood cell transfusion, platelet transfusion, or granulocyte colony-stimulating factor (G-CSF) within 7 days prior to the date of the test.
- •8. Participant must have Eastern Cooperative Oncology Group (ECOG) status of 0 or 1
- •9. Participant must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
- •10. A woman of childbearing potential must have a negative serum pregnancy test at screening and within 72 hours of the first dose of study treatment and must agree to further serum or urine pregnancy tests during the study.
- •11. A woman must be (as defined in Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information) either of the following:
- •a. Not of childbearing potential
- •b. Of childbearing potential and practicing true abstinence during the entire period of the study, including up to 6 months after the last dose of study treatment is given
- •c. Of childbearing potential and practicing 2 methods of contraception, including 1 highly effective user independent method and a second method
- •Participant must agree to continue contraception throughout the study and through 6 months after the last dose of study treatment.
- •- Note: If the childbearing potential changes after start of the study (eg, woman who is not heterosexually active becomes active, premenarchal woman experiences menarche) the woman must begin birth control, as described above.
- •12. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 6 months after receiving the last dose of study treatment.
- •13. A man must wear a condom when engaging in any activity
排除标准
- •1. Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for early stage Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease).
- •2. Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study. Participants who have received definitive radiation or surgical treatment for symptomatic or unstable brain metastases and have been clinically stable and asymptomatic for at least 2 weeks before randomization are eligible, provided they have been either off corticosteroid treatment or are receiving low-dose corticosteroid treatment (=10 mg/day prednisone or equivalent) for at least 2 weeks prior to randomization.
- •3. Participant has an active or past medical history of leptomeningeal disease.
- •4. Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid
- •treatment or receiving low-dose corticosteroid treatment =10 mg/day prednisone or equivalent.
- •5. Participant has uncontrolled tumor-related pain.
- •6. Participant has an active or past medical history of ILD/pneumonitis, including drug-induced or radiation ILD/pneumonitis.
- •7. Participant has an uncontrolled illness
- •8. Participant has concurrent or prior malignancy other than the disease under study.
- •9. Participant has active cardiovascular disease
- •10. Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib.
- •11. Participant is currently receiving medications or herbal supplements known to be potent CYP3A4/5 inducers and is unable to stop use for an appropriate washout period prior to randomization (see Appendix 8: Prohibited and Restricted Medications and
- •Therapies That Induce, Inhibit, or Are Substrates of CYP3A4/5).
- •12. Participant has received any prior treatment with an EGFR TKI.
- •13. Participant has received an investigational medication within 12 months before randomization or is currently enrolled in an investigational study.
- •14. Participant is pregnant, breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study treatment.
- •15. Participant plans to father a child while enrolled in this study or within 6 months after the last dose of study treatment.
- •16. Participant has any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
- •17. Participant has at Screening:
- •Positive hepatitis B (hepatitis B virus [HBV]) surface antigen (HBsAg)
- •Positive hepatitis C (hepatitis C virus [HCV]) antibody (anti-HCV)
- •Other clinically active infectious liver disease
- •18. Participant is positive for human immunodeficiency virus (HIV)
- •19.Participant had major surgery excluding placement of vascular access or tumor biopsy, or had significant traumatic injury within 4 weeks before randomization, or will not have fully recovered from surgery, or has surgery planne
研究者
相似试验
招募中
3 期
A Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer harboring EGFR Exon 19del or L858R mutations10029107NL-OMON54268Janssen-Cilag15
进行中（未招募）
1 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR-mutated locally advanced or metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000743-31-FRJanssen-Cilag International N.V.1,000
进行中（未招募）
1 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR-mutated locally advanced or metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-506576-27-00Janssen - Cilag International1,074
进行中（未招募）
1 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR-mutated locally advanced or metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000743-31-NLJanssen-Cilag International N.V.1,000
进行中（未招募）
1 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung CancerEGFR-mutated locally advanced or metastatic Non Small Cell Lung CancerMedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-000743-31-HUJanssen-Cilag International N.V.1,000